Novel compounds and their use as selective inhibitors of caspase-2

Abstract

【assignment】 To provide more selective and efficient caspase-2 inhibitors for use in the prevention and / or treatment of diseases and / or injuries involving caspase-2 activity. [Solution] This invention relates to a compound represented by formula (I). (In the formula, P1, P3, P4, and P5 are amino acid residues or amino acid-like structures.) Furthermore, the present invention relates to the use of a compound of formula (I) as a caspase-2 inhibitor and its therapeutic use. The present invention also relates to the use of a compound of formula (I) as an activity-dependent probe for selectively detecting caspase-2 activity. [Formula 1] [Selection Diagram] None

Description

[Technical Field]

[0001] The present invention relates to novel compounds useful as selective inhibitors of caspase-2. The present invention also relates to the therapeutic use of said compounds and their use as activity-dependent probes (ABPs) for caspase-2. [Background technology]

[0002] Caspases are a family of intracellular endoproteases that use cysteine ​​residues in the initiation of cleavage of peptide substrates. Caspases are widely known to have important roles in regulating programmed cell death by apoptosis, as well as having important implications in the regulation of inflammation.

[0003] Caspases are classified into two major groups: those involved in regulating inflammatory processes (caspase-1, -4, -5, -11, and -12) and those central to the initiation and execution of apoptosis. Apoptotic caspases are divided into two groups: "initiators" with long N-terminal prodomains (caspase-2, -8, -9, and -10), and those with short prodomains (20–30 residues) that are apoptotic "executors" (caspase-3, -6, and -7). Caspases involved in the initiation of inflammation and apoptosis possess structural units involved in the transmission of the apoptotic signal, such as the "death effector domain" (DED) and the "caspase-attracting domain" (CARD). Each of these domains allows for homotypic interactions with other protein partners.

[0004] The enzymatic properties of caspases are influenced by the presence of a catalytic dyad (cysteine, histidine), in which the cysteine ​​acts as a nucleophile to initiate peptide bond cleavage. The active site of caspases, the peptide sequence QACXG (where X is arginine (R), glutamine (Q), or glycine (G)), contains a catalytic cysteine, and a highly conserved basic subsite (S1), which confers specificity for substrate cleavage after aspartic acid residues and is unique among mammalian proteases except for the serine protease granzyme B. Caspases generally recognize a tetrapeptide motif P1-P4 at the N-terminus of the scissile bond, which is recognized by the enzyme's subsites S1-S4, respectively. The downstream aspartic acids (P'1 and P'2) are also involved in caspase recognition and specificity.

[0005] Caspases are classified into three groups based on the substrate peptide sequences they preferentially recognize. Group I caspases (-1, -4, and -5) preferentially recognize hydrophobic residues in P4. Group II enzymes (-2, -3, and -7) highly preferentially recognize aspartic acid at this position, while group III enzymes (-6, -8, -9, and -10) preferentially recognize small aliphatic chains at P4. Within group II, caspase-2 has a unique recognition mode. In fact, its catalytic activity requires recognition of a residue at the P5 position (preferably leucine, isoleucine, valine, or alanine). Caspases-3 and -7, on the other hand, recognize the P5 residue in a non-essential manner.

[0006] Caspase-2, originally named Nedd-2 for "neural progenitor cell-expressed developmentally downregulated 2" in mice and the human homolog of Ich-1, ICE, and CED3, encoded by the gene CASP2 (chromosome 7q34-q35), is the most conserved member of this enzyme family. Its activity is finely regulated during human neural development. Two caspase-2 isoforms exist: proapoptotic (2L) and antiapoptotic (2S). Isoform 2L is the predominant form in most tissues, whereas isoform 2S is expressed at similar levels in the brain, skeletal muscle, and heart.

[0007] Caspase-2 does not degrade many other caspases but can initiate mitochondrial outer membrane permeabilization and acts as an initiator caspase that regulates diverse stress-induced signaling pathways, including heat shock, DNA damage, mitochondrial oxidative stress, and cytoskeletal disruption.

[0008] In addition to apoptosis, caspase-2 is involved in regulating oxidative stress. For example, aged Casp-2- / - mice exhibit reduced superoxide dismutase and glutathione peroxidase activity. Under certain circumstances, caspase-2 may act as a tumor suppressor. Indeed, under oncogenic stress (such as in the Eμ-Myc transgenic mouse model), caspase-2 deficiency enhances tumor formation. Some data also suggest that caspase-2 may inhibit autophagy (Tiwari M et al., J Biol Chem 2011;286:8493-8506; Tiwari M et al. Autophagy 2014;10:1054-070).

[0009] Genetic inhibition of caspase-2 has been shown to be neuroprotective in neonatal mice exposed to hypoxia-ischemia or excitotoxic exposure, suggesting that caspase-2-mediated cell death may be involved in the pathophysiology of perinatal brain injury (Carlsson et al., Annals of Neurology 2011, 70(5):781-9). Furthermore, genetic inhibition of caspase-2 protects ocular neurons (Amhed Z et al., Cell Death Dis. 2011 Jun 16;2:e173), and caspase-2 has recently been shown to mediate site-specific retinal ganglion cell death after blunt ocular injury (Thomas CN et al., Invest Ophthalmol Vis Sci. 2018 Sep 4;59(11):4453-4462).

[0010] In cellular models of Alzheimer's disease (Carol M. Troy et al., The Journal of Neuroscience, February 15, 2000, 20(4):1386-1392), caspase-2 is a key effector of neuronal cell death induced by the amyloid peptide Aβ (Ribe EM et al., Biochem J. 2012 444(3):591-9).

[0011] Furthermore, Pozueta et al. (Nat Commun. 2013;4:1939) used amyloid precursor protein transgenic mice and (i) Caspase-2 is required for cognitive decline in this animal model of Alzheimer's disease; and (ii) Cultured hippocampal neurons lacking caspase-2 are immune to the synaptic toxic effects of Aβ. (iii) We showed that caspase-2 is a key mediator in the activation of the RhoA / ROCK-II signaling pathway, leading to dendritic spine collapse, and therefore suggested that caspase-2 is an important factor in synaptic dysfunction in Alzheimer's disease.

[0012] Caspase-2 has also been found to directly cleave tau protein, possibly contributing to the generation of Δtau314, which may contribute to the synaptic dysfunction observed in Alzheimer's disease and other tauopathies (Zhao et al., Nat. Med. 2016).

[0013] Caspase-2 also appears to be involved in the behavioral disorders of Huntington's disease (Caroll et al., Mol. Neurodegener. 2011 Aug 19;6:59).

[0014] Caspase-2 is also thought to promote obesity, metabolic syndrome, and nonalcoholic fatty liver disease, and indeed, caspase-2-deficient mice have been shown to be protected from these conditions (Machado MV et al., Cell Death Dis. 2016 Feb 18;7:e2096).

[0015] The first generation of caspase inhibitors were aldehyde peptides that reversibly inhibited caspases. Several sequences were developed that appeared to preferentially activate certain members of the caspase family, including Ac-DEVD-CHO (a preferential inhibitor of caspase-3 and caspase-7) and Ac-VDVAD-CHO (a preferential inhibitor of caspases-2, -3, and -7).

[0016] In second-generation caspase inhibitors, the aldehyde group is replaced with an α-substituted ketone containing a fluoromethylketone group (fmk). This type of inhibitor inactivates the enzyme by forming an adduct with the active site cysteine. Z(benzyloxylcarbonyl)-VAD-fmk is a broad-spectrum inhibitor of this generation. These molecules are toxic in vivo, especially in the liver, because release of the fluoroacetate group leads to inhibition of aconitase. Therefore, the development of inhibitors containing the fmk group was abandoned in the preclinical stage due to their hepatotoxicity. Subsequently, several caspase inhibitors have been synthesized in the art (Poreba et al., Chem Rev. 2015 Nov 25;115(22):12546-629). In particular, compounds capable of inhibiting caspase-2 activity have been reported, for example, in WO 2005 / 105829 and EP 2670774. However, these known caspase-2 inhibitors also have very high activity against caspase-3, and therefore, the compounds may not have the ability to act as selective caspase-2 inhibitors.

[0017] Recently, a series of reversible caspase-2 inhibitors have been reported. When evaluated in vitro with human recombinant caspases, these compounds were found to preferentially inhibit caspase-2, but had modest efficacy in cellular assays and structural properties incompatible with in vivo use (Maillard et al., Biorganic & Medicinal Chemistry 19 (2011) 5833-5851). [Prior art documents] [Patent documents]

[0018] [Patent Document 1] WO2005 / 105829 [Patent Document 2] EP2670774 [Non-patent literature]

[0019] [Non-Patent Document 1] Tiwari M et al., J Biol Chem 2011;286:8493-8506 [Non-patent document 2] Tiwari M et al. Autophagy 2014;10:1054-070). [Non-patent document 3] Carlsson et al., Annals of Neurology 2011,70(5):781-9). [Non-patent document 4] Amhed Z et al. Cell Death Dis.2011 Jun 16;2:e173 [Non-patent document 5] Thomas CN et al., Invest Ophthalmol Vis Sci.2018 Sep 4;59(11):4453-4462 [Non-patent document 6] Carol M. Troy et al., The Journal of Neuroscience, February 15, 2000, 20(4):1386-1392 [Non-Patent Document 7] Ribe EM et al., Biochem J. 2012 444(3):591-9 [Non-patent document 8] Pozueta et al., Nat Commun.2013;4:1939 [Non-Patent Document 9] Zhao et al., Nat. Med. 2016. [Non-Patent Document 10] Caroll et al., Mol. Neurodegener.2011 Aug 19;6:59 [Non-Patent Document 11] Machado MV et al. Cell Death Dis.2016 Feb 18;7:e2096 [Non-Patent Document 12] Poreba et al., Chem Rev. 2015 Nov 25;115(22):12546-629 [Non-Patent Document 13] Maillard et al., Biorganic &Medicinal Chemistry 19(2011)5833-5851 Summary of the Invention [Problem to be solved by the invention]

[0020] Thus, there remains a need for potent and selective caspase-2 inhibitors that have significantly reduced activity against caspase-3. It would be highly advantageous to provide more selective and efficient caspase-2 inhibitors, particularly for use in the prevention and / or treatment of diseases and / or injuries involving caspase-2 activity, such as neonatal cerebral ischemia, cardiac ischemia, and chronic degenerative diseases such as Alzheimer's disease.

[0021] It would also be highly advantageous to provide more effective and selective caspase-2 inhibitors for use as activity-dependent probes for the specific detection of caspase-2 activity.

[0022] The compounds of the present invention are intended to meet these needs. [Means for solving the problem]

[0023] Thus, according to one of its aspects, the present invention provides a compound of formula (I) or one of its salts, The compounds of formula (I) relate to all possible racemates, enantiomers and diastereoisomers of the compounds.

[0024] [ka] (wherein Z1 and Z2 are the same or different and are selected from a hydrogen atom, a (C1-C6) alkyl group, and a (C1-C6) alkoxy group). P5 is selected from the following amino acid residues or amino acid-like structures:

[0025] [ka] - P1 and P4 are the same or different and are selected from the following amino acid-like structures:

[0026] [ka] wherein Z3 and Z4 are the same or different and are selected from a hydrogen atom and a (C1-C6) alkyl group. - P3 is selected from the following amino acid residues:

[0027] [ka] R1 is selected from the following formula:

[0028] [ka] -R2 is selected from the following formula:

[0029] [ka] (In the formula, m is 0, 1 or 2; p is 1, 2, 3 or 4; ·Z5 is a halogen atom; q is 0 or 1; Z6 is selected from (C1-C6) alkyl and phenyl groups, the phenyl groups optionally being substituted with amino groups; Z7, Z8 and Z 11 are the same or different and are selected from a hydrogen atom, a (C1-C4) alkyl, a tetrahydroquinolinyl, and a -(CH2)i-aryl group, where i is 0, 1 or 2, and the aryl group is optionally substituted with 1, 2, 3 or 4 halogen atoms or a (C1-C4) alkyl group; Z9 and Z 10 are the same or different and are selected from halogen atoms and (C1-C6) alkyl groups.

[0030] After extensive research, the present inventors have found that the compounds of formula (I) act as selective and effective inhibitors of caspase-2 activity, as demonstrated in the examples below.

[0031] In fact, the compounds of the present invention inhibit caspase-2 more efficiently than they inhibit caspase-3.

[0032] In particular, as shown in the Examples below, some compounds of the present invention exhibit inhibitory effects against caspase-2 that are at least 2-fold, preferably at least 5-fold, more preferably at least 10-fold, and even more preferably at least 15-fold greater than their inhibitory effects against caspase-3.

[0033] The inhibitory effects of the compounds of the present invention on caspase-2 and caspase-3 can be evaluated by a kinetic approach using human recombinant caspases. For irreversible inhibitors, the method shown in Example 2 below can be used. inact / K I For reversible inhibitors, the IC 50 and k i Measure.

[0034] Furthermore, the fact that some of the inhibitors are irreversible is highly advantageous, as this type of inhibitor can be used in the sustained inhibition of caspase-2, limited only by the normal rate of protein resynthesis, also known as turnover.

[0035] Within the meaning of this specification: "Caspase inhibitor" is intended to mean a compound that reduces or inhibits the activity of a targeted caspase compared to said activity measured in the absence of said inhibitor. - "selective caspase-2 inhibitor" is intended to mean a compound that reduces the activity of caspase-2 relative to the activity of other caspases, in particular caspase-3.

[0036] Thus, according to a second aspect, the present invention is directed to a compound of the invention for its use as a selective caspase-2 inhibitor.

[0037] According to one embodiment, the R2 group of the compounds of the invention is selected from the following formulae:

[0038] [ka] (In the formula, m, p, q, Z5, Z6, Z7, Z8, Z9, Z 10 and Z 11 is as defined above.)

[0039] The compounds can be advantageously incorporated into pharmaceutical compositions. They can be used as medicines. More specifically, they can be used in the prevention and / or treatment of diseases and / or injuries in which caspase-2 activity is involved.

[0040] For the purposes of the present invention, the term "prevention" means at least partially reducing the risk of a given phenomenon, i.e., in the present invention, the occurrence of a disease and / or disorder in which caspase-2 activity is implicated. A partial reduction means that the risk remains, but to a lesser extent than before the present invention was performed.

[0041] For the purposes of the present invention, the term "treatment" is intended to mean the complete or partial cure of a given phenomenon, i.e., a disease and / or disorder in which caspase-2 activity is involved, including, in the present invention, the reduction, minimization or reduction of said given phenomenon.

[0042] Thus, according to a third aspect, the present invention is directed to a pharmaceutical composition comprising at least one compound of the invention, wherein R2 is as defined above, and at least one pharmaceutically acceptable excipient.

[0043] According to a fourth aspect, the present invention is directed to a compound of the invention wherein R2 is as defined above, for use as a medicament.

[0044] According to a fifth aspect, the present invention is directed to a compound of the invention, wherein R2 is as defined above, for use in the prevention and / or treatment of diseases and / or disorders in which caspase-2 activity is involved.

[0045] According to a sixth aspect, the present invention is directed to a compound of the invention, wherein R2 is as defined above, for use in protecting neurons from Aβ-induced dysfunction or undesirable effects induced by Aβ, in particular Aβ-induced cell death, Aβ-induced axonal degeneration, Aβ-induced electrophysiological dysfunction, and / or Aβ-induced synapse loss.

[0046] According to another embodiment, the R2 group of the compounds of the present invention is selected from the following formulae:

[0047] [ka]

[0048] Said compounds can advantageously be used as activity-dependent probes for selectively detecting caspase-2 activity.

[0049] Thus, according to a sixth aspect, the present invention is directed to the use of a compound of the invention wherein R2 is as defined above as an activity-dependent probe for selectively detecting caspase-2 activity.

[0050] In the context of the present invention, the following abbreviations and empirical formulas are used: -Boc Tert-butyloxycarbonyl -℃ degree Celsius temperature -Me methyl -Bn benzyl -AMC 7-amino-4-methylcoumarin -PBS Phosphate Buffered Saline -Ac acetyl -RFU relative fluorescence units -HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid -DTT Dithiothreitol -EDTA Ethylenediaminetetraacetic acid -CHAPS (3-((3-cholamidopropyl)dimethylammonio)-1-propanesulfonic acid -DMSO Dimethyl sulfoxide

[0051] It is further noted that in all amino acid-like sequences represented herein by the use of the above abbreviations, the left-right orientation is the conventional direction from amino terminus to carboxy terminus.

[0052] Thus, in the formulas defining the peptide-like structures of the present invention, when a sequence such as R1-P5P4P3- or -P1-R2 is shown, it is clear that: (i) P5 amino acid residue or amino acid-like residue

[0053] [ka] The moiety is bonded to R1; one of the P4 amino acid-like residues is linked to a P5 amino acid residue or amino acid-like residue; One of the P3 amino acid residues is bound to a P4 amino acid-like residue; One of the P1 amino acid residues is opposite to R2 as shown in formula (I).

[0054] [ka] is bound to; (ii) P5 amino acid residue or amino acid-like residue

[0055] [ka] The portion is bound to a P4 amino acid-like residue; one of the P4 amino acid residues is bound to a P3 amino acid residue; One of the P3 amino acid residues is opposite to the P4 amino acid residue as shown in formula (I).

[0056] [ka] is bound to; One of the P1 amino acid residues is bound to R2.

[0057] Other features and advantages of the present invention will become more apparent from the detailed description and the following examples given as non-limiting examples. [Brief explanation of the drawings]

[0058] [Figure 1] Synaptic protection against amyloid beta peptide [1-42] oligomer toxicity by Compound 2. Co: Control; [Aβ]nβ: Neurons incubated with 10 nM amyloid beta peptide [1-42] oligomer; Aβ: Neurons pretreated with 0.1 μM or 1 μM of Compound 2 enantiomer and then intoxicated with 10 nM amyloid beta peptide [1-42] oligomer. (**p<0.01 (Kruskal-Wallis-Dunn post-hoc test)) DETAILED DESCRIPTION OF THE INVENTION

[0059] Compounds of the Invention As mentioned above, the compound of the present invention is a compound represented by formula (I) or one of its salts: The compounds represented by formula (I) are compounds in all conceivable racemates, enantiomers and diastereoisomers.

[0060] [ka] (Wherein Z1 and Z2 are the same or different and are selected from a hydrogen atom, a (C1-C6) alkyl group and a (C1-C6) alkoxy group; P5 is selected from the following amino acid residues or amino acid-like structures:

[0061] [ka] and - P1 and P4 are the same or different and are selected from the following amino acid-like structures:

[0062] [ka] and wherein Z3 and Z4 are the same or different and are selected from a hydrogen atom and a (C1-C6) alkyl group. - P3 is selected from the following amino acid residues:

[0063] [ka] and R1 is selected from the following formula:

[0064] [ka] and -R2 is selected from the following formula:

[0065] [ka] and (In the formula, m is 0, 1 or 2; p is 1, 2, 3 or 4; ·Z5 is a halogen atom; q is 0 or 1; Z6 is selected from (C1-C6) alkyl and phenyl groups, the phenyl groups optionally being substituted with amino groups; Z7, Z8 and Z 11 are the same or different and include a hydrogen atom, (C1-C4) alkyl, tetrahydroquinolinyl, and —(CH2) i-aryl groups, where i is 0, 1 or 2, and the aryl group is optionally substituted with 1, 2, 3 or 4 halogen atoms or a (C1-C4) alkyl group; Z9 and Z 10 are the same or different and are selected from halogen atoms and (C1-C6) alkyl groups.

[0066] In certain embodiments,

[0067] [ka] The asymmetric carbon atom of the pyrrolidine ring attached to is in the (S) configuration, and other asymmetric alpha carbon atoms of the amino acid, such as P1, P3, P4 and P5, are in the (S) configuration.

[0068] In a more particular embodiment,

[0069] [ka] The asymmetric carbon atom of the pyrrolidine ring attached to is in the (R) configuration, and the other asymmetric alpha carbon atoms of the amino acid, such as P1, P3, P4 and P5, are in the (S) configuration.

[0070] The compounds of the present invention therefore contain several asymmetric carbon atoms. They can therefore exist in the form of enantiomers or diastereoisomers. These enantiomers and diastereoisomers, as well as mixtures thereof, including racemic mixtures, form part of the present invention.

[0071] The compounds of the present invention can also exist in the form of bases or acid addition salts. These salts can be prepared with pharmaceutically acceptable acids, but also salts of other acids that are useful, for example, for purifying or isolating the compounds of formula (I) form part of the invention.

[0072] The term "pharmaceutically acceptable" generally means something useful for preparing pharmaceutical compositions that are safe, non-toxic, and not biologically or otherwise undesirable, and includes something acceptable for veterinary and human pharmaceutical use.

[0073] The compounds of the invention may also exist in the form of hydrates or solvates, i.e. in the form of associations or combinations with one or more water molecules or with a solvent. Such hydrates and solvates also form part of the invention.

[0074] In the context of the present invention, the following definitions apply: - halogen atom: a fluorine, chlorine, bromine or iodine atom. The halogen atom may in particular be a fluorine atom. -C t -C Z : a carbon-based chain possibly containing t to z carbon atoms, where t and z can take values ​​from 1 to 10; for example, C1-C3 is a carbon-based chain possibly containing 1 to 3 carbon atoms. - alkyl: a linear or branched saturated aliphatic group, especially containing 1 to 6 carbon atoms. Examples which may be mentioned are methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, neopentyl, etc. - Alkoxy: O-alkyl group, wherein the alkyl group is as defined above. - Aryl: A monocyclic or bicyclic aromatic group containing 5 to 10 carbon atoms, in particular 6 to 10 carbon atoms. Examples of aryl groups include phenyl and naphthyl groups. Preferably, the aryl group is phenyl.

[0075] Among the compounds of general formula (I) of the present invention, a subgroup of compounds is the compounds of formula (II), and said compounds represented by the above formula (II) are constituted by all conceivable racemates, enantiomers and diastereoisomers of the compounds.

[0076] [ka] (In the formula, R1 and R2 are as defined above in formula (I); -Z1 and Z2 are as defined above in formula (I); -R3 is selected from -CH3, -CH(CH3)2, -CH2CH(CH3)2, -CH(CH3)CH2CH3, and a 4-hydroxyphenyl group; A and B are the same or different and are selected from a nitrogen atom and a —CH— group; R5 and R6 are the same or different and are selected from a hydrogen atom and a (C1-C6) alkyl group; -R4 is selected from -CH3, -CH(CH3)2, -CH2CH(CH3)2, -CH(CH3)CH2CH3 and -(CH2)2CO2H groups.

[0077] In certain embodiments,

[0078] [ka] The asymmetric carbon atom of the pyrrolidine ring attached to is in the (S) configuration, and other asymmetric alpha carbons of the amino acid, such as P1, P3, P4 and P5, are in the (S) configuration.

[0079] In a more particular embodiment,

[0080] [ka] The asymmetric carbon atom of the pyrrolidine ring attached to is in the (R) configuration, and the other asymmetric alpha carbons of the amino acid, such as P1, P3, P4 and P5, are in the (S) configuration.

[0081] Preferably, in formula (II), at least one of A and B is a —CH group, more preferably A and B are —CH groups.

[0082] According to a preferred mode of the present invention, the compound of the present invention is of formula (III) or one of its salts, and the compound represented by formula (III) may be in any conceivable racemate, enantiomer, and diastereoisomer form.

[0083] [ka] (wherein R1 and R2 are as defined in formula (I) above).

[0084] According to another preferred embodiment, in formula (I), (II) and / or (III), R1 is represented by the following formula:

[0085] [ka]

[0086] According to another preferred embodiment, in formula (I), (II) and / or (III), R1 is represented by the following formula:

[0087] [ka]

[0088] According to another preferred embodiment, in formula (I), (II) and / or (III), R2 is selected from the following formulae:

[0089] [ka] (wherein Z' is a fluorine atom, j is 0, 1 or 2, and R2 is preferably represented by the following formula):

[0090] [ka]

[0091] In certain embodiments, when R2 is methoxyphenyl as defined above, the phenyl ring is substituted with 2, 3, 4 or 5 halogen atoms, preferably the halogens are selected from fluorine or chlorine atoms.

[0092] According to a further preferred embodiment, the compounds of the present invention have at least one, preferably at least three, asymmetric carbon atoms of the (S) configuration.

[0093] In certain embodiments,

[0094] [ka] The asymmetric carbon atom of the pyrrolidine ring attached to is in the (S) configuration, and other asymmetric alpha carbon atoms of the amino acid, such as P1, P3, P4 and P5, are in the (S) configuration.

[0095] More preferably, all asymmetric carbon atoms in the compounds of the present invention are in the (S) configuration.

[0096] In a more particular embodiment,

[0097] [ka] The asymmetric carbon atom of the pyrrolidine ring attached to is in the (R) configuration, and the other asymmetric alpha carbon atoms of the amino acid, such as P1, P3, P4 and P5, are in the (S) configuration.

[0098] Among the compounds of general formula (I) according to the invention, mention may in particular be made of the following compounds:

[0099] [Table 1]

[0100] [Table 2]

[0101] Thus, in certain embodiments, the compound of the present invention is selected from compounds 1-6 described herein above.

[0102] Preparation of Compounds of the Invention The compounds of the present invention can be prepared by organic synthesis and peptide synthesis. The construction of structures by peptide synthesis is common knowledge to those skilled in the art, and further details are disclosed in Linton et al., J.Med.Chem.2005,48,6779-6782 and Chauvier et al., Cell Death Dis 2011,2:e203. The precursors of R1, R2, P1, X, P3, P4 and P5 that lead to the compounds of the present invention are introduced in several different steps of the method.

[0103] The precursors may be either commercially available products or commercially available products functionalized by protocols well known to those skilled in the art. Further details and references can be found in "Design of Caspase Inhibitors as Potential Clinical Agents; CRC Press; CRC Enzyme Inhibitors Series, Edited by Tom O'Brien & Steven D. Linton, Chapter 7 by BR Ullman.

[0104] In particular, Example 1 of the present invention illustrates a protocol for the preparation of compound 2 of the present invention.

[0105] application As previously stated and as clearly demonstrated by the examples below, the compounds of the present invention are useful as selective caspase-2 inhibitors.

[0106] In fact, as pointed out in the Examples, although caspase-3 and caspase-2 have the most similar active sites among all caspases, the compounds of the present invention are shown to have a superior inhibitory effect on caspase-2 than on caspase-3. As a result, they are effective in selectively inhibiting caspase-2.

[0107] a) Therapeutic Areas In view of the above, the compounds of the present invention, in particular those in which the R2 group

[0108] [ka] (In the formula, m, p, q, Z5, Z6, Z7, Z8, Z9, Z 10 and Z 11 Compounds selected from the group consisting of (wherein R is as defined above) can be used in the therapeutic field.

[0109] Thus, according to one of its aspects, the present invention relates to compounds of the invention, wherein R2 is as defined above, for use in medicine, in particular in medicine intended to selectively inhibit caspase-2.

[0110] In other words, the present invention relates to the use of a compound of the invention, wherein R2 is as defined above, for the preparation of a medicament, in particular a medicament for selectively inhibiting the activity of caspase-2.

[0111] In other words, the present invention relates to a medicament, in particular a medicament for selectively inhibiting the activity of caspase-2, comprising at least one compound of the invention, wherein R2 is as defined above.

[0112] Therefore, according to another aspect, the present invention is directed to compounds of the invention, wherein R2 is as defined above, for use in the prevention and / or treatment of diseases and / or disorders in which caspase-2 activity is involved.

[0113] In other words, the present invention relates to compounds of the invention, wherein R2 is as defined above, for the preparation of a medicament intended for the prevention and / or treatment of diseases and / or disorders in which caspase-2 activity is involved.

[0114] In particular, said disease and / or disorder may be a pathology involving cell death, in particular selected from: - chronic degenerative diseases such as Alzheimer's disease or other tauopathies, Huntington's disease and Parkinson's disease; - neonatal brain disorders, especially neonatal cerebral ischemia; -Traumatic brain injury; -renal ischemia; -Hypoxic (HI) ischemia; - Stroke-like brain injury; -cardiac ischemia; - Myocardial infarction; -Amyotrophic lateral sclerosis (ALS); - retinal disorders; -Ocular diseases such as blunt eye injury, ischemic optic neuropathy and glaucoma; -Skin damage; - sterile inflammatory diseases such as diabetes, atherosclerosis, cardiac ischemia, gout, pseudogout, loose joints, atherosclerosis, aluminum salt-induced syndrome, non-arteriogenic anterior ischemic optic neuropathy (NAION), glaucoma and metabolic diseases; - non-sterile inflammatory diseases such as bacterial infections, especially infections with bacteria that produce pore-forming toxins, influenza virus infections and rhabdovirus infections with single-stranded (ss) RNA, e.g. Maraba virus or vesicular stomatitis virus (VSV); -Diseases caused by pathogenic bacteria such as Brucella, Staphylococcus aureus and Salmonella; -dyslipidemia; - obesity; - metabolic syndrome; and - Non-alcoholic fatty liver disease

[0115] More particularly, said diseases and / or disorders are selected from chronic neurodegenerative diseases, preferably Alzheimer's disease, other known tauopathies (primary age-related tauopathies, chronic traumatic encephalopathy, progressive supranuclear palsy, corticobasal degeneration, frontotemporal dementia, Parkinson's disease linked to chromosome 17, dementia complex disease, ganglioglioma and gangliocytoma, meningioangiomatosis, postencephalitic parkinsonism, subacute sclerosing panencephalitis, lead encephalopathy, tuberous sclerosis complex, pantothenate kinase-associated neurodegeneration, lipofuscinosis, etc.), Huntington's disease and Parkinson's disease, in particular Alzheimer's disease.

[0116] According to another aspect, the present invention is directed to compounds of the invention, wherein R2 is as defined above, for use in synaptic protection, more particularly in the prevention and / or treatment of neurodegenerative diseases, even more particularly Alzheimer's disease or tauopathies.

[0117] In one embodiment, the present invention is directed to a compound selected from Compound 2, Compound 3, Compound 4, Compound 5 and / or Compound 6 above, for use in the prevention and / or treatment of Alzheimer's disease or other tauopathies.

[0118] In a further embodiment, the present invention is directed to compound 2 as defined above for use in the prevention and / or treatment of Alzheimer's disease or other tauopathies.

[0119] In a further embodiment, the present invention is directed to compound 3 as defined above for use in the prevention and / or treatment of Alzheimer's disease or other tauopathies.

[0120] In a further embodiment, the present invention is directed to compound 4 as defined above for use in the prevention and / or treatment of Alzheimer's disease or other tauopathies.

[0121] In a further embodiment, the present invention is directed to compound 5 as defined above for use in the prevention and / or treatment of Alzheimer's disease or other tauopathies.

[0122] In a further embodiment, the present invention is directed to compound 6 as defined above for use in the prevention and / or treatment of Alzheimer's disease or other tauopathies.

[0123] In a particular embodiment, the invention relates to said compounds for use in the prevention and / or treatment of Alzheimer's disease.

[0124] In one embodiment of the invention, the invention is directed to a compound selected from compound 2, compound 3, compound 4, compound 5 and / or compound 6 as defined above for use in the prevention and / or treatment of Alzheimer's disease.

[0125] In a further embodiment, the present invention is directed to compound 2 as defined above for use in the prevention and / or treatment of Alzheimer's disease.

[0126] In a further embodiment, the present invention is directed to compound 3 as defined above for use in the prevention and / or treatment of Alzheimer's disease.

[0127] In a further embodiment, the present invention is directed to compound 4 as defined above for use in the prevention and / or treatment of Alzheimer's disease.

[0128] In a further embodiment, the present invention is directed to compound 5 as defined above for use in the prevention and / or treatment of Alzheimer's disease.

[0129] In a further embodiment, the present invention is directed to compound 6 as defined above for use in the prevention and / or treatment of Alzheimer's disease.

[0130] More specifically, as shown in the experimental section, the compounds of the present invention in which R2 is defined above are effective in protecting neuronal cells from Aβ oligomer-induced dysfunction or undesirable effects.

[0131] Thus, according to a further aspect, the present invention is directed to a compound of the present invention, wherein R2 is as defined above, for use in protecting neuronal cells from Aβ-induced dysfunction or undesirable effects, more particularly Aβ-induced cell death, Aβ-induced axonal degeneration, Aβ-induced electrophysiological dysfunction, and / or Aβ-induced synapse loss.

[0132] In one embodiment, the present invention is directed to a compound selected from Compound 2, Compound 3, Compound 4, Compound 5 and / or Compound 6, as defined above, for use in protecting neuronal cells from Aβ-induced dysfunction or undesirable effects, more particularly Aβ-induced cell death, Aβ-induced axonal degeneration, Aβ-induced electrophysiological dysfunction, and / or Aβ-induced synaptic loss.

[0133] In a further embodiment, the present invention is directed to compound 2 as defined above for use in protecting neuronal cells from Aβ-induced dysfunction or undesirable effects, more particularly Aβ-induced cell death, Aβ-induced axonal degeneration, Aβ-induced electrophysiological dysfunction, and / or Aβ-induced synapse loss.

[0134] In a further embodiment, the present invention is directed to compound 3 as defined above for use in protecting neuronal cells from Aβ-induced dysfunction or undesirable effects, more particularly Aβ-induced cell death, Aβ-induced axonal degeneration, Aβ-induced electrophysiological dysfunction, and / or Aβ-induced synapse loss.

[0135] In a further embodiment, the present invention is directed to compound 4 as defined above for use in protecting neuronal cells from Aβ-induced dysfunction or undesirable effects, more particularly Aβ-induced cell death, Aβ-induced axonal degeneration, Aβ-induced electrophysiological dysfunction, and / or Aβ-induced synapse loss.

[0136] In a further embodiment, the present invention is directed to compound 5 as defined above for use in protecting neuronal cells from Aβ-induced dysfunction or undesirable effects, more particularly Aβ-induced cell death, Aβ-induced axonal degeneration, Aβ-induced electrophysiological dysfunction, and / or Aβ-induced synapse loss.

[0137] In a further embodiment, the present invention is directed to compound 6 as defined above for use in protecting neuronal cells from Aβ-induced dysfunction or undesirable effects, more particularly Aβ-induced cell death, Aβ-induced axonal degeneration, Aβ-induced electrophysiological dysfunction, and / or Aβ-induced synapse loss.

[0138] In another aspect, the present invention is directed to a method for preventing and / or treating diseases and / or disorders in which caspase-2 activity is involved, comprising at least the step of administering to an individual in need of prevention and / or treatment at least an effective amount of at least one compound of the present invention, wherein R2 is as defined above.

[0139] According to another aspect, the present invention relates to a pharmaceutical composition comprising at least one compound of the invention, wherein R2 is as defined above, and at least one pharmaceutically acceptable excipient.

[0140] The pharmaceutical compositions of the present invention may more particularly contain an effective amount of at least one compound of the present invention in which R2 is as defined above.

[0141] By "effective amount" is meant an amount sufficient to induce a positive improvement in the condition or disorder being controlled or treated, but low enough to avoid serious side effects. The effective amount may vary depending on the pharmaceutical effect to be obtained or the particular condition being treated, the age and health of the end user, the severity of the condition or disorder being treated / prevented, the duration of treatment, the nature of other treatments, the particular compound or product / composition used, the route of administration, and similar factors.

[0142] The compounds of formula (I) of the present invention, wherein R2 is as defined above, can be administered in an effective amount by any of the art-recognized modes.

[0143] In one embodiment, the compounds can be used in compositions intended to be administered by oral, nasal, sublingual, ophthalmic, topical, rectal, vaginal, urethral, ​​or parenteral administration.

[0144] The route of administration and the galenical formulation will be adapted by those skilled in the art according to the desired pharmaceutical effect.

[0145] One of ordinary skill in the art can ascertain therapeutically effective doses of the compounds of the invention for a given indication without undue experimentation or reliance on personal knowledge.

[0146] The pharmaceutical composition of the present invention can be formulated with any known suitable pharmaceutically acceptable excipient depending on the dosage, galenic form, administration route, etc.

[0147] As used herein, "pharmaceutically acceptable excipients" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, etc. Except insofar as any conventional excipient is incompatible with the active compound, its use in the medicament or pharmaceutical composition of the invention is contemplated.

[0148] The medicaments or pharmaceutical compositions of the present invention may be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols, sprays, ointments, gels, creams, sticks, lotions, pastes, soft and hard gelatin capsules, suppositories, sterile injectable solutions, sterile packaged powders, and the like.

[0149] According to one embodiment, the pharmaceutical compositions of the present invention are intended for separate, sequential or simultaneous administration with other drugs useful in the prevention and / or treatment of pathologies, in particular Alzheimer's disease, other than the compounds of formula (I) of the present invention.

[0150] b) Activity-dependent probes The compounds of the present invention, more specifically,

[0151] [ka] A compound selected from the following can be used as an activity-dependent probe for selectively detecting caspase-2.

[0152] Thus, according to one aspect, the present invention relates to the use of the compounds of the invention, wherein R2 is as defined above, as activity-dependent probes (ABPs) for selectively detecting caspase-2 activity.

[0153] The present invention will be better understood by reference to the following examples, which are provided for illustrative purposes only and should not be construed as limiting the invention in any manner. [Example]

[0154] Example 1: Preparation of Compound 2 of the Invention The synthesis of the compounds of the present invention can be achieved by the preparation method of compound TRP601 shown below.

[0155] [ka]

[0156] The synthesis of TRP601 is disclosed in D. Chauvier et al., Cell Death and Disease (2011) 2, e203.

[0157] For example, compound 2 of the present invention differs from TRP601 in the following respects. P1 and P4 are represented by the following [Chemical Formula 34] instead of the following [Chemical Formula 35] in TRP601;

[0158] [ka]

[0159] [ka] and The proline-like residue shown below in [Chemical formula 36] is used instead of the residue shown below in [Chemical formula 37] in TRP601.

[0160] [ka]

[0161] [ka]

[0162] Therefore, compound 2 can be prepared by using the following precursor [Chemical formula 38] instead of the following [Chemical formula 39] to introduce the P1 and P4 residues:

[0163] [ka]

[0164] [ka] To introduce a proline-like residue having an asymmetric carbon atom of either configuration (R or S) bonded to the following [Chemical formula 40], except that the following precursor [Chemical formula 41] is used instead of the following [Chemical formula 42]:

[0165] [ka]

[0166] [ka]

[0167] [ka] Compound 2 is obtained by reproducing the steps disclosed in the above publication to give TRP601.

[0168] The precursors of P1 and P4 were prepared according to protocols well known to those skilled in the art, starting from commercially available (S)-aspartic acid, in which the amine function is protected by a Boc group.

[0169] The proline precursor was obtained as described by Maillard et al., in Bioorganic & Medicinal Chemistry 19 (2011): 5833-5851.

[0170] The other components of Compound 2 were introduced in the same manner as TRP601 in the publication, ie, with the same reagents, under the same conditions, and in the same amounts.

[0171] Therefore, compound 2 is

[0172] [ka] The pyrrolidine asymmetric carbon atom attached to the amine may have either configuration (R or S), and may be obtained in greater than 90% yield and characterized by HPLC.

[0173] Example 2: Caspase-2 and Caspase-3 Inhibition Assay for Irreversible Inhibition (In Vitro) The inhibitory efficacy of compounds of the present invention, which are irreversible inhibitors of caspase-2 and caspase-3, can be evaluated using the protocol described below. Compound 2, as well as compounds 4, 5, and 6, are irreversible inhibitors and were evaluated accordingly.

[0174] The efficacy of the comparative compound Δ2Me-TRP601, a known group II caspase inhibitor (inhibitor of caspase-2, caspase-3, and caspase-7), was evaluated using a protocol similar to that disclosed in Chauvier et al., 2011 Cell Death Dis 2011, 2:e203.

[0175] The two test compounds are shown below:

[0176] [ka]

[0177] In this example, caspase-2 and caspase-3 are human recombinant active enzymes supplied by Enzo Life® (ALX-201-057-U100) and R&D Systems® (707-C3-010 / CF), respectively.

[0178] Caspase-2 is used at a final concentration of 0.1 nM in "caspase-2 buffer" containing 20 mM HEPES (pH 7.4), 5 mM DTT, 2 mM EDTA, 0.1% CHAPS, and 800 mM succinic acid. Caspase-3 is used at a final concentration of 0.5 nM in "caspase-3 buffer" containing 20 mM HEPES (pH 7.4), 0.1% CHAPS, 5 mM DTT, and 2 mM EDTA.

[0179] The peptide substrates used for enzyme activity measurements are Ac-DEVD-AMC and Ac-VDVAD-AMC (referred to as ALX-260-031-M005 and ALX-260-060-M005, respectively) commercially available from EnzoLife®. The compounds are fluorescent due to the presence of an AMC (7-amino-4-methylcoumarin) end group. Release of AMC allows for the tracking of enzyme activity in fluorescent units (RFU) over time in 96-well microplates.

[0180] Fluorescence values ​​are measured spectrofluorometrically at 37°C using a BMG FLUOstar OPTIMA microplate reader. The instrument is driven by the Biolise software and equipped with a thermoelectric cooling device using the Peltier effect. Mathematical analysis of the experimental data is performed using the Kaleidagraph software.

[0181] The inhibitory properties of test compounds were assessed using a kappa-based assay with respect to either caspase-2 or caspase-3. inact / K I Evaluated by determining the ratio.

[0182]

number

[0183] Thus, the higher the ratio, the more effective the inhibitor.

[0184] The ratio is measured by the continuous method (Allison RD. Curr Protoc Protein Sci. 2001 May; Chapter 3: Unit 3.5.; Chauvier et al., 2011 Cell Death Dis 2: e203; Tan et al., J Med Chem 2015, 58: 598-312).

[0185] Briefly, caspase activity was measured using a BMG Fluostar microplate reader (black 96-well microplate) by monitoring the hydrolysis of a fluorogenic substrate (λexc = 355 nm, λem = 460 nm) as a function of time in the presence of untreated caspase (control) or caspases incubated with test compounds for 30 min at 37°C, and the initial velocity (V0) was determined from the linear portion of the progress rate curve.

[0186] Substrates and compounds were pre-dissolved in DMSO to 10 mM, and the final solvent concentration was kept below 4% (v / v). V, relative velocity, K M and IC 50 was determined from experimental data using Mars Data Analysis 2.0 and Kaleidagraph software.

[0187] For an irreversible inhibitor as compound 2, the inactivation can be represented by a minimal kinetic scheme where E and I are the free forms of the enzyme and inhibitor, E*I is the kinetic chimera of the Michaelis complex, and EI is the covalent complex or inactivated enzyme.

[0188]

number

[0189] For caspase-2 and caspase-3, inhibitor binding affinity (dissociation constant, K I ) and first-order rate constant (k3) parameters were determined using the progress curve method. The ratio k3 / K I was obtained by fitting the experimental data to the formula (FU, fluorescence units).

[0190]

number

[0191] Linear and nonlinear regression fitting of experimental data to equations was performed with Kaleidagraph software.

[0192] k of caspase-2 and caspase-3 activity inact / K I Ratio Measurement k inact / K I A serial ratiometric method was used to evaluate the inhibitory activity of test compounds against caspase-2 and caspase-3.

[0193] The reaction mixture is prepared by incubating the enzyme and buffer at 37°C.

[0194] Test inhibitor compounds were tested at several different concentrations (IC 50 1 / 4 of IC 50 1 / 2;IC50;IC 50 Twice as much as IC 50 Prepare a 4x solution of 100 ml of PBS (4x the original volume) and place it in a microplate.

[0195] A reaction mixture containing enzyme, buffer and substrate is then quickly added to the wells.

[0196] Enzyme activity is measured between 45 and 60 minutes.

[0197] The RFU (relative fluorescence units) = f (time) curve is followed for each concentration of the test molecule according to the following formula: ((((-V0)*(exp(-k obs *m0)))+V0) / k obs *)+RFU0 During the ceremony, -V0 is the initial velocity (RFU.s) at zero concentration of the test inhibitory compound -1 ) corresponds to; -k obs is the inactivation rate constant; -RFU0 is the fluorescence value at t=0; -m0 is a variable, i.e., the inhibitor concentration.

[0198] Adjust the hyperbolic curve f([I]) = k(k) using Kaleigagraph software and calculate k based on the following equation: inact / k I Get the ratio. K obs =k inact ×[I] / (K I ×[I])

[0199] The k values ​​thus obtained for compounds 2, 3, 5, and 6, and Δ2Me-TRP601, with respect to caspases 2 and 3, were inact / K I Comparison of the ratios allows assessment of their selectivity.

[0200] [Table 3]

[0201] The compounds tested are found to be effective in inhibiting caspase-2.

[0202] However, compound 2 behaves quite differently than Δ2Me-TRP-601 with respect to caspase 3 (see Table 2 below).

[0203] [Table 4]

[0204] ND: No inhibitory activity detected. +++: No inhibitory activity detected against casp3, so selectivity is very significant (>>1000).

[0205] Indeed, compound 2 inactivates caspase-2 much more efficiently than it inactivates caspase-3, whereas Δ2Me-TRP601 does not exhibit this selectivity.

[0206] In conclusion, compound 2 is not only efficient in inhibiting caspase-2, but is also selective for caspase-2 compared to caspase-3.

[0207] [ka] It is noteworthy that the level of caspase-2 inhibition is found to vary greatly depending on the configuration (R or S) of the asymmetric carbon atom of the pyrrolidine ring to which it is attached. The compounds of the present invention provide particularly interesting inhibitors of caspase-2 that are moderately or potently, yet highly specific (Table 2).

[0208] Example 3: Caspase-2 and caspase-3 activity detection To measure the efficiency of substrates for individual caspases, we used the K cat / K M Measure K cat (s -1 ) is the catalytic constant, or the number of substrate molecules converted to product per unit time by each active site when the enzyme is saturated, and KM, which indicates the enzyme-substrate affinity, is the Michaelis-Menten constant, and v = V max is the substrate concentration for / 2.

[0209] Caspase-2 (or caspase-3) is incubated with the enzyme and inhibitor dissolved in the Michaelis-Menten complex or buffer alone for 30 minutes at 37°C. The reaction is initiated by the addition of a buffer-substrate mixture in a total volume of 100 μL. Enzyme activity is then measured over a 20 minute period. The release of the fluorogenic AMC group is detected using the following wavelengths: λexc = 360 nm and λem = 460 nm.

[0210] [Table 5]

[0211] Enzyme activity is expressed as the initial velocity value (V i ), where V max is the rate at which the enzyme is saturated with the substrate, and [S] is the substrate concentration. Here, RFU.min -1The initial velocity, denoted as F(time)=RFU, is experimentally obtained from the slope value of the linear part of the F(time)=RFU curve, a value calculated directly by the Biolise® software. Vi = Vmax × [S] / (Km + [S]) (eq. 1) The initial velocity (V0) obtained for the control is considered to be 100% of the enzyme activity. Inhibition is characterized by an activity less than 100% after treatment with an inhibitor. The percentage of inhibition is calculated from equation 2 (eq. 2), where V0 is the initial velocity of the inactive control and Vi is the initial velocity in the presence of the inhibitor. Inhibition rate (%)=(1-(V0 / Vi))×100(eq.2)

[0212] Example 4: Caspase-2 and caspase-3 inhibition assays for reversible inhibitors The inhibitory efficacy of compounds of the present invention that are reversible inhibitors of caspase-2 and caspase-3 can be evaluated using the protocol described below: Compound 3 is a reversible inhibitor and is evaluated accordingly.

[0213] A preliminary step in the characterization of an inhibitor is to determine its IC50, which is the concentration of inhibitor required to reduce enzyme activity to 50% of its maximal, uninhibited value.

[0214] Different concentrations of compound are incubated with enzyme and buffer at 37°C for 30 minutes to allow the formation of enzyme-inhibitor complexes. The reaction is initiated by adding buffer and substrate, and activity is measured over 15 minutes to determine the initial rate. The percent inhibition of the analyzed compound as a function of its concentration generally follows the hyperbolic transformation equation 3 (eq. 3). The equation is entered into Kaleidagraph software to fit the curve f([I]) = % inhibition (where [I] is the inhibitor concentration) to obtain the IC50. Inhibition rate (%)=100×[I] / (IC50+[I])(eq.3)

[0215] Evaluation of reversible inhibitors The reversibility of inhibition by Ac-VDVAD-CHO, Ac-DEVD-CHO, and compound 3 is analyzed by the dilution method. The enzyme and inhibitor (or DMSO as a control) are incubated for 30 min at 37 °C. The complex thus formed is diluted 1:100 with a buffer / substrate mixture, after which activity measurements are initiated over a 20 min period. The initial velocity obtained with DMSO represents 100% activity and serves as a basis for quantifying the residual activity of the enzyme in the presence of the inhibitor.

[0216] To characterize a reversible inhibitor, the dissociation constant, Ki, is determined. The dissociation constant provides a basis for the inhibitor's affinity for the enzyme. To do this, the inhibitor competes with the substrate for the enzyme's active site. If, after dilution, activity is restored to 50% or more, the inhibitor is said to be "reversible."

[0217] Inhibitors were added at different concentrations (IC 50 1 / 4 of IC 50 1 / 2 of IC 50 ;I C 50 Twice as much as IC 50 The reaction is incubated with a caspase buffer mixture at 4x the concentration of the enzyme (4x the concentration of the enzyme) for 30 minutes at 37° C. The reaction is initiated by adding the buffer-substrate mixture and is carried out for 20 minutes.

[0218] RFU.min -1 The initial rate value, expressed as , decreases from the AMC standard range to the specific activity (SA) value (pmol / min / μg enzyme) (1 RFU → 0.02 pmol).

[0219] By expanding the ratio 1 / SA as a function of 1 / [S], ​​the so-called Lineweaver-Burk double inverse graph can be obtained from equation 4 (eq. 4), where Vmaxapp and KMapp are parameters that vary depending on the type of inhibition and as a function of the inhibitor concentration. The intersection of the lines obtained with increasing inhibitor concentration makes it possible to distinguish between different types of inhibitors.

[0220]

number

[0221] From the value of the slope of the Lineweaver-Burk plot, a quadratic graph obtained as a function of the inhibitor concentration allows to obtain the Ki value, the value of which is given by the abscissa point at the origin.

[0222] The inhibitory potency of compounds on Casp-2 and -3 was measured using IC 50 The results are shown in Table 3 (left). In terms of efficacy against Casp-2, the IC 50 This value places it next to the reference compound Ac-VDVAD-CHO (IC50 = 6.9 nM). In addition to acting efficiently on Casp-2, compound 3 also exhibits a similar activity to Ac-VDVAD-CHO (IC 50 = 7.23 nM). Thus, compound 3 is Casp-2 selective.

[0223] A detailed study of the inhibition mechanism was carried out as follows.

[0224] The initial velocity V0 is expressed by Equation 8. In the following equation, Vmax is the maximum reaction velocity (reached when the enzyme is saturated with substrate), [S] is the substrate concentration, KM is the Michaelis-Menten constant (the substrate concentration corresponding to Vmax / 2), and K i is the dissociation constant, which indicates the affinity of the inhibitor for the enzyme. i The inhibitory power can be quantified by the following equation: the lower the value, the more potent the inhibitor.

[0225]

number

[0226] The secondary tracks obtained from the Lineweaver-Burk graph data allow us to i The K values ​​of various inhibitors could be determined. i The values ​​and selectivity index are shown in Table 4 (right side).

[0227] [Table 6]

[0228] [Table 7]

[0229] Inhibitory efficiency is expressed as IC50 values ​​for the Ac-DEVD-CHO and Ac-VDVAD-CHO reference inhibitors and the P2 mutant Ac-VDVAD-CHO derivatives (Table 4). Quantification of inhibition is indicated by the value of the Ki constant, which indicates the affinity of the inhibitor for the enzyme. A lower value indicates a more potent inhibitor for its target. The ratio of the constants quantifies selectivity (Table 5); the higher the ratio, the more selective the inhibitor is for Casp-2.

[0230] The Ki values ​​confirm and complement the information provided by the IC50 data. Thus, compound 3 remains a potent inhibitor of Casp-2, with significantly increased selectivity for the latter compared to Ac-VDVAD-CHO (Table 5).

[0231] Example 5: Protection against cell death assay In this example, the protective effect of compound 2 of the present invention against cell death induced by vincristine (a vinca alkaloid) is tested using a well-known flow cytometric cell death assay based on propidium iodide staining.

[0232] a) Cellular Models To assess the protective effects of compounds 2 and 3, a caspase-dependent cellular model is used.

[0233] This model uses human HeLa cells (a cervical cancer cell line) obtained from the American Type Cell Collection (ATCC) and cultured in Dulbecco's modified Eagle's medium (DMEM, High Glucose, GlutaMAX™, Pyruvate) (Gibco, Life Technologies) supplemented with 10% FCS and antibiotics (Gibco, Life Technologies).

[0234] Human HeLa cells are treated with vincristine (Sigma-Aldrich) solution (diluted to 5 mM in water). Vincristine partially binds to the protein tubulin, which functions to stop cells from separating chromosomes during division. The cells then undergo apoptosis via a caspase-dependent process.

[0235] Propidium iodide (PI) (Sigma Aldrich) is used to assess cell membrane permeability, a sign of cell death.

[0236] b) Treatment and marking conditions HeLa cells were seeded in 24-well plates 24 hours before drug treatment. The culture medium was then removed, the cells were washed with PBS, and fresh medium containing different concentrations of Compound 2 or 3 was added 1 hour before the addition of vincristine. The cells were exposed to 20 nM vincristine for 48 hours or not (control).

[0237] The contents of each well are collected and added to PBS, then centrifuged (900 rpm; 5 min).

[0238] The resulting pellet is placed in 300 μL of medium containing propidium iodide and incubated in the dark for 5 minutes (37° C., 5% CO 2 ) before flow cytometry analysis.

[0239] c) cell analysis The cells are then analyzed by flow cytometry using 561 nm excitation.

[0240] Fluorescence-activated cell sorting was performed using a FACSCalibur cytometer (Becton Dickinson, San Jose, CA). For each sample, data from 5,000 cells were registered and analyzed using CellQuest Pro™ software (Becton Dickinson). Analysis included FSC (forward scatter / related to cell size) and SSC (cell scatter / related to cell granularity) parameters along with the FL-1 and FL-3 channels.

[0241] [Table 8]

[0242] Cell death is estimated from the percentage of propidium iodide-positive cells.

[0243] A control composition containing neither vincristine nor inhibitor allows for an estimation of the amount of spontaneous cell death.

[0244] A composition containing vincristine but no inhibitor provides a total number of dead cells corresponding to the sum of spontaneously dead cells and apoptotic cells induced by vincristine.

[0245] We clearly observe that compounds 2 and 3 protect cells from apoptotic death induced by vincristine in a dose-dependent manner.

[0246] Example 6: Protection against beta neurotoxicity a) Primary neuronal culture Hippocampi are microdissected from E16 embryos of C57B16 / J wt mice (Rene Janvier, France) in cold Gey's Balanced Salt Solution (GBSS, Sigma) supplemented with 0.1% glucose (Life technologies).

[0247] Dissected structures were digested with papain (20 U / mL in DMEM, Sigma, St. Louis, MO, USA) and mechanically dissociated in the presence of DNAse. Hippocampal cells were then rinsed, resuspended in DMEM (Life Technologies, Inc., Gaithersburg, MD, USA), washed in Neurobasal (Life Technologies) supplemented with B27 (1 / 50) and 1% penicillin / streptomycin (Gibco) and lutamax (0.1% Life Technologies), and resuspended to a final density of 18 million cells / mL.

[0248] This cell suspension is then used to fill the reservoir of the microfluidic chamber as previously described (Peyrin et al., 2011 Lab Chips 11(21):3663; Deleglise et al., 2014 Acta Neuropathologica Comm. 2:145). The microfluidic chip is placed in a plastic Petri dish containing H2O-EDTA and incubated at 37°C in a humidified 5% CO2 atmosphere to prevent evaporation. The medium is changed every 7 days.

[0249] b) Preparation of Aβ peptide oligomers Oligomeric Aβ 1-42 (Tocris Bioscience, MN, USA) was prepared according to Stine WB et al. (2003) in J Biol Chem 278, pp 11612-11622 and could be examined by electron microscopy as described by Deleglise B et al. in Acta Neuropathol Commun. 2014;2:145.

[0250] Briefly, the lyophilized Aβ peptide was dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP, Sigma-Aldrich) at a concentration of 1 mM. After a 30-minute incubation at room temperature, the HFIP was evaporated for 12 hours under a chemical hood, and the peptide was dried for 1 hour (using a Speed ​​Vac at 4°C). The peptide was then redissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich) to obtain a 5 mM peptide stock solution. To obtain oligomers, the Aβ peptide stock solution was diluted with chilled phenol-free DMEM-F12 medium (Life Technologies) to a final concentration of 100 μM. The solution was then incubated at 4°C for 24 hours. The soluble Aβ oligomer fraction was collected from the supernatant after a centrifugation step at 20,000 g (10 minutes at 4°C) and stored at -80°C until use.

[0251] c) Toxicity testing After 18 days of culture in the microfluidic chamber, hippocampal cells were pre-incubated for 1 hour with compounds of the present invention pre-diluted in phenol-free DMEM-F12 medium or with phenol-free DMEM-F12 medium as a control solution. The cells were then incubated with 10 or 100 nM Aβ. 1-42 Cells were inoculated with the oligomer (or phenol-free DMEM-F12 medium alone as a control) for 3–6 or 24 hours. After inoculation, cells were fixed with 4% paraformaldehyde (PFA, Sigma; St. Louis, MO, USA) for 20 minutes at room temperature and then labeled as described below to assess synaptic status, cell death, or axonal degeneration.

[0252] d) Immunofluorescence Briefly, after the fixation step, the cultured cells were washed twice for 5 minutes with PBS + 0.1% azide and permeabilized for 10 minutes with a solution of 0.2% Triton X-100 and 0.1% BSA (bovine serum albumin, Sigma) in PBS containing 0.1% azide. A saturation step was then performed by incubating the cells for 30 minutes with PBS containing 0.1% azide and 1% BSA. The primary antibody was then added, and the samples were incubated overnight in PBS at 4°C. The samples were then washed twice for 5 minutes with PBS containing 0.1% azide and incubated with the corresponding secondary antibody together with phalloidin conjugated to Alexa Fluor 555. The chips were then washed twice with PBS containing 0.1% azide.

[0253] The following antibodies were used: rabbit polyclonal anti-MAP-2 (AB5622; 1 / 400, MILLIPORE), mouse monoclonal anti-Bassoon SAP7F407 (1:400, Enzo LifeSciences), species-specific secondary antibodies conjugated to Alexa 350, 488, or 500 (1 / 500, Life Technologies, Inc., Gaithersburg, MD, USA), and phalloidin conjugated to Alexa Fluor 555 (1 / 500, Enzo LifeTechnologies) were used to stain F-actin.

[0254] e) Image acquisition Images were acquired with an Axio-observer Z1 (Zeiss, Germany) equipped with a cooled CCD camera (Coolsnap pHQ2, Ropert Scientific). The microscope was controlled with Metamorph and Micro-manager software. Images were analyzed using ImageJ software.

[0255] f) Results Aβ-intoxicated cells not pretreated with the compounds of the present invention exhibited a significant decrease in anti-Bassoon labeling as soon as 6 hours after intoxication compared with non-intoxicated samples. Dendritic spines were reduced in mouse hippocampal neurons, demonstrating neurodegeneration due to Aβ synaptic toxicity, with a significant decrease in synapse number (approximately 50%, Figure 1). Furthermore, 24 hours after Aβ treatment, axonal degeneration was observed in hippocampal neurons not pretreated with the compounds of the present invention. The compounds of the present invention are shown to be effective in protecting hippocampal cells from Aβ-induced cell death, Aβ-induced axonal degeneration, Aβ-induced electrophysiological dysfunction, and / or Aβ-30-induced synapse loss (Table 7 and Figure 1).

[0256] [Table 9]

[0257] The above experiments provide evidence that compounds of the present invention capable of modulating the activity of caspase-2 (Tables 1 and 5) are effective in treating or preventing the development of disorders associated with Aβ neurotoxicity.

[0258] Conclusion: Thus, the compounds of the present invention are useful compounds for treating diseases associated with cell death or dysfunction mediated by caspase-2 activity. More specifically, the compounds of the present invention may prove effective in treating neurodegenerative diseases such as Alzheimer's disease (AD), in which Aβ synaptotoxicity is known to be important in the pathophysiology of the disease. Furthermore, since caspase-2 is known in the art to mediate the cleavage of tau to generate Δtau314, which is involved in the cognitive decline of AD, the compounds of the present invention may be valuable compounds for use in the treatment or prevention of diseases in which either tau and / or Aβ toxicity is involved.

Claims

1. A compound of formula (I) or one of its salts: 【Chemistry 1】 (In the formula, Z １ is a hydrogen atom; Z ２ is —CH 2 —C(CH 3 ) 3; P ５ is selected from the following amino acid residues or amino acid-like structures: 【Chemistry 2】 P １ and P ４ is expressed by the following formula: 【Transformation 3】 (Wherein, Z3 is a hydrogen atom and (C １ ) alkyl groups) P ３ is selected from the following amino acid residues: 【Chemistry 4】 R １ is expressed by the following formula: 【Transformation 5】 and R ２ is selected from the following formula: 【Transformation 6】 (In the formula, m is 0, 1 or 2; p is 1, 2, 3 or 4; Z ５ is a halogen atom; q is 0; Z ８ Ha-(CH ２ )-phenyl group, said phenyl group containing 1, 2, 3 or 4 halogen atoms or 1 (C １ -C ４ ) optionally substituted with an alkyl group; Z １１ (C １ -C ４ ) alkyl group; and Z ９ and Z １０ are the same or different, and a halogen atom and (C １ -C ６ ) alkyl groups)

2. The compound according to claim 1, which is a compound represented by formula (II) or one of its salts: 【Transformation 7】 (In the formula, R １ and R ２ is as defined in formula (I) of claim 1; Z １ and Z ２ is as defined in formula (I) of claim 1; R ３ is -CH ３ , -CH(CH ３ ) ２ , -CH ２ CH (CH ３ ) ２ , -CH(CH ３ ) CH ２ CH ３ and a 4-hydroxyphenyl group; A and B are CH groups; R ５ and R ６ are the same or different and are selected from a hydrogen atom and a (C1) alkyl group; R ４ is -CH ３ , -CH(CH ３ ) ２ , -CH ２ CH (CH ３ ) ２ , -CH(CH ３ ) CH ２ CH ３ and -(CH ２ ) ２ CO ２ H groups)

3. A compound according to claim 1 or 2, which is a compound represented by formula (III) or one of its salts: 【Transformation 8】 (In the formula, Z 1 , Z 2 , R １ and R ２ is as defined in formula (I) of claim 1.

4. The R ２ is selected from the following formula: 【Chemistry 9】 (wherein Z′ is a fluorine atom and j is 0, 1 or 2). The R ２ is preferably represented by the following formula: 【Chemistry 10】 The compound according to any one of claims 1 to 3.

5. A compound, which is one of the compounds represented by the formula selected from the following or a salt thereof. 【Chemistry 11】

6. A composition for use as a selective caspase-2 inhibitor, comprising a compound according to any one of claims 1 to 5.

7. A pharmaceutical composition comprising at least one compound according to any one of claims 1 to 5 and at least one pharmaceutically acceptable excipient.

8. A composition for use as a pharmaceutical, comprising a compound according to any one of claims 1 to 5.

9. A composition for use in the prevention and / or treatment of diseases and / or disorders involving caspase-2 activity, comprising a compound described in any one of claims 1 to 5.

10. Pathologies involving cell death, in particular chronic degenerative diseases such as Alzheimer's disease or tauopathies, Huntington's disease and Parkinson's disease; neonatal brain damage, in particular neonatal cerebral ischemia; traumatic brain injury; renal ischemia; hypoxic-ischemic (HI) injury; stroke-like brain damage; cardiac ischemia; myocardial infarction; amyotrophic lateral sclerosis (ALS); retinal disorders; eye diseases such as blunt eye injury, ischemic optic neuropathy and glaucoma; skin injuries; diabetes, atherosclerosis, cardiac ischemia, gout, pseudogout, joint loosening, atherosclerosis, aluminum salt-induced syndrome, non-arteriogenic ischemic optic neuropathy.

10. The composition of claim 9 for use in the prevention and / or treatment of sterile inflammatory diseases such as neuropathy (NAION), glaucoma and metabolic diseases; non-sterile inflammatory diseases such as bacterial infections, particularly infections with bacteria that produce pore-forming toxins, influenza virus infections and single-stranded (ss) RNA, e.g., rhabdovirus infections such as Maraba virus or vesicular stomatitis virus (VSV); diseases caused by pathogenic bacteria such as Brucella, Staphylococcus aureus and Salmonella; dyslipidemia; obesity; metabolic syndrome; and non-alcoholic fatty liver disease.

11. The composition of claim 10 for use in the prevention and / or treatment of Alzheimer's disease.

12. 10. The composition of claim 9 for use in protecting neuronal cells from Aβ-induced dysfunction or undesirable effects induced by Aβ, in particular Aβ-induced cell death, Aβ-induced axonal degeneration, Aβ-induced electrophysiological dysfunction, and / or Aβ-induced synapse loss.

Images